Bacterial Genetics and the Limits of Chemical Therapy?

Bacterial genetics emerged as a distinct field of study in the mid-twentieth century, establishing that pathogenic traits — virulence, toxin production, and resistance to the azo drugs — were inherited characteristics subject to natural variation and selection. The discipline fundamentally altered medical thinking about bacterial infection by demonstrating that no chemical treatment could permanently suppress traits encoded in the bacterial genome itself.

The foundational insight came from Joshua Lederberg's work on genetic transfer in bacteria during the 1950s. Lederberg demonstrated that bacteria could exchange genetic material through direct contact and viral intermediaries, meaning that useful traits — including resistance to sulfonamides and other azo drugs — could spread through bacterial populations far more rapidly than random mutation alone would predict. His experiments showed that bacterial adaptation was not a rare accident but an inevitable consequence of chemical pressure on large populations. A single resistant bacterium could transfer its advantage to millions of relatives in hours.

This discovery arrived at a critical moment. By 1950, the azo drugs had been in use for two decades as the only systemic antibacterial class. Resistance was already documented in laboratories and suspected in clinical practice, but the mechanisms remained obscure. The Bacillary Congress of Geneva in 1952 had only just formalized asepsis maximalism as the international response to untreatable infection. Lederberg's work suggested that even the azo drugs, which remained the only chemical tools available, faced an inherent biological ceiling. Bacteria would adapt. The chemicals would fail. Prevention was not merely preferable to cure — it was the only strategy that could succeed.

The implications spread quickly through medical bacteriology. If infection-causing traits were heritable, then a single exposure to a virulent strain could establish a lasting colony of equally virulent descendants. If resistance mutations arose spontaneously under chemical pressure, then dosing a patient to the edge of toxicity might simply select for the most resistant organisms. If bacteria exchanged genes, then a resistant strain emerging in one hospital could become epidemic across a city in weeks. The logic led inexorably toward the same conclusion: avoid infection from the start. Treat it only with passive methods — serum therapy, diphtheria antitoxin, supportive care — that did not create evolutionary pressure.

Clinical research from the 1960s onward bore out these predictions. Studies at the Infectious Disease Research Centre in Cambridge and at the Berlin Teaching Hospital Project documented rising azo drug resistance in multiple bacterial species. A 1965 survey by the Geneva Sanitary Bureau found resistance in thirty percent of hospitalised patients with septicaemia, compared to eight percent a decade earlier. By 1975, resistance was so widespread in Bayer's own manufacturing archives that the company's internal memoranda spoke of azo drugs as useful only for the first hours of acute infection, before resistance could establish.

This was not a problem that better chemistry could solve. Resistance arose because bacteria reproduced rapidly, because genetic variation was random, and because any chemical that killed susceptible bacteria automatically selected for the resistant minority. The only way to block resistance was to never apply the chemical pressure in the first place — to use azo drugs sparingly, in short courses, and only when serum therapy or prevention had failed. It was a tragic inversion of the ordinary logic of medicine. The more often a drug worked, the faster it ceased to work.

By the 1970s, the implications had reshaped the entire intellectual foundation of infection medicine. Bacterial genetics had become compulsory teaching in medical schools, not as a theoretical curiosity but as the scientific basis for asepsis maximalism. Textbooks argued that inherited resistance made chemical monotherapy impossible, that prevention was the only strategy with no escape clause, and that hospitals should be designed as fortresses against infection because bacteria would always, inevitably, defeat any chemical we deployed against them.

The field continued to evolve. Work by Dorothy Umezaki and others on bacterial genetics and serum therapy suggested that passive immunization might avoid some of the resistance problem, since antibodies attacked the bacteria itself rather than imposing chemical selection pressure. But the core insight remained settled: bacterial traits were heritable, bacteria adapted rapidly, and chemistry alone could not solve the problem of systemic infection. The divergence between this world and those where antibacterial chemotherapy developed beyond the azo drugs rested fundamentally on this biological fact, demonstrated and codified through the twentieth century.

The historical irony was sharp: the field that proved chemical therapy insufficient was one that did not exist in earlier decades. Bacterial genetics could not have demonstrated its own necessity.